Summary: This study was designed to evaluate whether Hybrid Capture II (HC2) test alone refer women to colposcopy as appropriately as DNA Papanicolaou (Pap) test, in the context of a high-risk group of women using the recently validated DNACitoliqÒ LBC system. Women with suspected cervical disease were included in this crosssectional study at a tertiary center in São Paulo, Brazil, for further workup. All women had cervical material collected for LBC and HC2 for high-risk human papillomavirus (hrHPV)-DNA test. Irrespective of cytology and HC2 results, colposcopy, and cervical biopsy when applicable, was systematically performed. All tests were performed blindly. Sensitivity, specificity, positive and negative predictive values, and overall accuracy of both methods were computed in relation to histology. A total of 1,080 women were included: 36.4% (393/1080) had ACUS+, 10.2% (110/1080) were high-grade squamous intraepithelial lesions (HSIL) or cancer. Mean age was 33.5 years. All women underwent colposcopy, and cervical biopsies were performed in 38.4% (415/1080): 33% (137/415) of the biopsies were negative, 14.4% (155/415) were low-grade squamous intraepithelial lesions (LSIL), 10.7% (116/415) were HSIL, and 0.6% (7/415) were cancer. HC2 sensitivity to diagnose biopsy-proven HSIL was 100%. Because all HSIL cases had a positive HC2 test, sensitivity could not be improved by adding LBC. Specificity and positive and negative predictive values of DNA Pap were not significantly different from HC2 test alone when considering LSIL+ histology as ''gold standard'' and HSIL+ histology. As a screening strategy for women with high-risk for cervical cancer, DNA Pap test does not seem to add substantially to HC2 alone in terms of appropriately referring to colposcopy.
The new century has brought new technologies to optimize cervical cancer screening. The introduction of liquid-based cytology (LBC) with preservative liquid medium, allowing for both cell morphology analysis and nucleic acids preservation for molecular tests, has led to a considerably higher detection rate of high-grade squamous intraepithelial lesions (HSIL) (1, 2) . Previously, the Hybrid Capture II (HC2) assay for high-risk human papillomavirus (hrHPV) (Digene Corp., Gaithersburg, MD) had been approved as a follow-up test for women who had abnormal or equivocal Papanicolaou (Pap) tests. More recently, the Food and Drug Administration (3) has granted approval to the HPV DNA test to be used simultaneously with LBC Pap test to screen for cervical cancer in women aged 30 years and older. The American Society of Gynaecology also has recommended the use of HC2 for equivocal cytology (4) . Combination of LBC and HC2 for hrHPV has been reported as a useful technical option for equivocal diagnoses (5) and to enhance the interval of screening (6) . The high negative predictive value (NPV) of HC2 hrHPV-DNA test (HC2) is assumed to be trustworthy enough to delay the screen interval (5-7). Interestingly, the combined LBC primary smear and HPV testing with a 5-year interval is similar in both cost and effectiveness to the other 3-yearly options of primary smear testing or primary HPV testing alone (8) . Despite the recognized success of conventional Pap test in the history of cervical cancer screening, its limitations, namely those related to the high false-negative rates, are well known. Its low sensitivity is a significant problem with public health implications (9) . HPV testing has superior sensitivity than cytology, but lower specificity. Taken together, combining Pap test and HPV testing seems promising (10) .
The use of HPV test as an adjunct technique to improve cervical screening was first proposed more than a decade ago (11) . Ever since, several purposes to change the orthodox prevention organization have been reported to optimize the classic system based on the primary screening with cytology, followed by colposcopy, biopsy, if necessary, and treatment (12) . The recently approved DNA Pap test is a hopeful strategy for cervical cancer screening to combine the sensitivity of HC2 test and the specificity of cytology (3). However, is not known whether strategies that have been shown to be cost-effective to screen the general population could be safely recommended to screen special groups of women with high risk for cervical cancer or its precursors.
This study was designed to evaluate whether Hybrid Capture II test alone refer women to colposcopy as appropriately as DNA Pap test, in the context of a high-risk group of women using the recently validated DNACitoliqÒ LBC system.
MATERIALS AND METHODS
From January through December 2002, consecutive women with suspected cervical disease on the grounds of an abnormal Pap test, and/or altered visual cervical inspection were referred for further workup at The Pérola Biygnton Hospital, São Paulo, Brazil. All women had cervical material collected for LBC and HC2 for hrHPV-DNA test. Irrespective of cytology and HC2 results, colposcopy, and cervical biopsy, when applicable, was systematically performed. LBC, HC2 tests, and histologic evaluation were processed at the Pathology Division of Adolfo Lutz Institute. All tests were performed blindly. The institutional review boards of both institutions involved in the project approved the study protocol.
The brush from the DNA-CitoliqÒ System (DCS; Digene Brasil, São Paulo, Brazil) was used to collect cervical material, and subsequently placed into tubes containing 1 ml of the conservative liquid Universal Collection Medium (UCMÒ). Once at the laboratory, batches of 12 DCS samples were simultaneously prepared in 10 to 15 minutes. In that system, the specimen in the slide is contained in a 25-mm-diameter circle. Cytology results were reported using the terminology of the Bethesda 2001 System (13), with the exception that atypical squamous (ASC-US) and glandular (AGC) cells of undetermined significance were grouped in one variable referred to as ACUS.
HC2 test was performed according to the instructions of the manufacturer. Only the probe for high-risk HPV was used.
Histologic specimens were initially evaluated according to WHO classification of squamous lesions in three classes (CIN 1, 2, and 3) (14) . However, for the purposes of statistical analyzes, results were presented in two categories: low-grade squamous intraepithelial lesions (LSIL) (CIN 1) and HSIL (CIN 2 and 3).
Statistical Analysis
Sensitivity, specificity, positive (PPV), and negative (NPV) predictive values of HC2, LBC, and DNA Pap in diagnosing women with cervical disease were calculated having both HSIL+ and LSIL+ histologic results as ''gold standard.'' The cutoff for a positive LBC was ACUS or higher (ACUS+). HC2 was deemed positive if the relative light units (RLU) were 1 or greater. The McNemar chi-square test was used to test for statistical differences in diagnostic parameters of the three screening strategies. Impact on diagnostic parameters of changing histologic cutoff from LSIL to HSIL was assessed by the chi-square test. A difference was statistically significant if p < 0.05. Data were stored and analyzed using the SPSSÒ statistical software, version 10.1 (SPSS Inc., Chicago, IL).
RESULTS
Of 1,095 women included in the study, 15 had unsatisfactory LBC preparation and were excluded. Among the remaining 1,080 women, 36.4% (393/1080) had a LBC showing ACUS+, 10.2% (110/1080) being HSIL or cancer. Mean age was 33.5 (range, 16-73) years. All women underwent colposcopy, and cervical biopsies were performed in 38.4% (415/1,080). Thirty-three percent (137/415) of those biopsies were negative, 14.4% (155/415) were LSIL, 10.7% (116/415) were HSIL, and 0.6% (7/415) were cancer.
The diagnostic parameters of HC2, LBC, and combined HC2 and LBC (DNA Pap) in relation to histology are shown in Table 1 . HC2 sensitivity to diagnose biopsyproven HSIL was 100%, whereas it declined to 84.2% in case the definition of a positive histologic result was downgraded to LSIL+ (p < 0.0001). In contrast, there is an increment on HC2 specificity when the histologic definition switches from HSIL+ (42.8%) to LSIL+ (59.1%) (p = 0.002). The same pattern is observed with LBC and DNA Pap.
To assess the diagnostic contribution of LBC in this high-risk population, sensitivity, specificity, and predictive values of DNA Pap were compared with same diagnostic parameters of HC2 test alone (Tables 2 and 3) . Because all HSIL cases had a positive HC2 test, sensitivity could not be improved by adding LBC. Specificity and positive and negative predictive values of DNA Pap were not significantly different from HC2 test alone when considering LSIL+ histology as ''gold standard'' and HSIL+ histology.
Sensitivity and NPV when diagnosing HSIL+ histology were significantly higher for HC2 test than for LBC, whereas LBC had greater specificity and PPV (Table 2) . For LSIL histology, HC2 test and LBC had similar predictive values (Table 3) .
DISCUSSION
In the present investigation of high-risk women for cervical cancer and its precursors, the diagnostic performance of HC2 test alone to detect HSIL+ was similar to combined LBC and HC2 test (DNA Pap). All histologically proven HSIL+ were detected by HC2 and DNA Pap, as opposed to nine cases missed by LBC. Furthermore, specificity, PPV, and NPV for HC2 test and DNA Pap were not statistically different. The definition of a positive histologic result (LSIL+ or HSIL+) greatly influences the diagnostic parameters of the three screening strategies. Similarly, if DNA Pap is computed as positive only when both HC2 and LBC are positive also will significantly influence diagnostic parameters of the tests.
In the present study, DNA Pap was computed as positive when HC2 or LBC were positive. All remaining combinations of the two screening tests were computed as a negative DNA Pap. Such definitions prioritize sensitivity at the expense of specificity. Indeed, the observed 100% sensitivity of DNA Pap for detecting HSIL+ would have significantly decreased to 92.7% (p < 0.0001) had the definition of a positive DNA Pap been both HC2 test and LBC positive.
In this group of high-risk women for cervical cancer included in this study, adding LBC to HC2 test did not add in terms of subsequent patient management. In fact, considering HSIL+ or LSIL+ as ''gold standard,'' the sensitivity, specificity, and predictive values of HC2 alone and DNA Pap test did differ significantly (Tables 2  and 3 ). This finding is in sharp contrast to what has been The histologic cutoff chosen as ''gold standard,'' LSIL+ or HSIL+, has a clear impact on the diagnostic parameters of the screening tests being assessed (Table 1) . Sensitivity increases when HSIL is the cutoff and consequently specificity will decrease. Which cutoff to choose will depend on the goal set for the screening program that is being evaluated. A possible objective could be to detect all HSIL, whereas a more comprehensive goal would be the detection of all lesions. In that case, the cutoff should be LSIL+.
In conclusion, as a screening strategy for women with high-risk for cervical cancer, DNA Pap test does not seem to add substantially to HC2 alone in terms of appropriately referring to colposcopy.
